MSD shocked over medicines council: "We have a system that doesn't work"

Pharmaceutical company MSD is puzzled by the Danish Medicines Council's choice to temporarily halt its reassessment of the firm's cancer remedy Keytruda in a specific lung indication after a meeting on Wednesday, even though it's now been two years since the European Medicines Agency approved the drug.

The Danish Medicines Council's choice to postpone its decision on approving MSD's cancer remedy prompts criticism. Photo: MSD / PR

Pharmaceutical company MSD once again has to prepare for a waiting period prior to knowing whether the Danish Medicines Council will approve its big seller, cancer remedy Keytruda (pembrolizumab) targeting a particular type of lung cancer.

Quite unexpectedly, the council elected during its latest meeting on Wednesday to put the remedy, which would benefit at least 300 patients a year, on temporary hold, so-called extended clock-stop.

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

Related articles